The lat­est Cin­derel­la sto­ry in on­col­o­gy ends with a sud­den rout as up­dat­ed da­ta dis­play spooks in­vestors

NextCure’s turn as the Cin­derel­la of can­cer-fo­cused biotechs was short-lived.

Just a few days af­ter its shares $NXTC zoomed up more than 250% on some very ear­ly stage re­sults in a SITC ab­stract, a more com­plete analy­sis over the week­end spiked the hype and left in­vestors in high dud­geon as the stock price col­lapsed back to­wards earth Mon­day.

The fo­cus at NextCure is cen­tered on NC318, an an­ti­body that is in­tend­ed to shut down the im­muno­sup­pres­sive Siglec-15 — or S-15 — tar­get. Af­ter adding a small group of pa­tients to the read­out, in­ves­ti­ga­tors cir­cled 2 clin­i­cal re­spons­es, a com­plete and par­tial re­sponse, along with 4 sta­ble dis­ease cas­es in non-small cell lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER